ERBB2 and breast cancer: However, significant differences in the prevalence of KRASmt G12C were observed in HRASmt vs. HRASwt in HR+/HER2- BC (5.9 vs. 0.1%), HNSCC (2.7 vs. 0.1%), squamous NSCLC (8.9 vs. 2.6%), and UC (5.8 vs. 0.4%) (all p < 0.05).